Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.52 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.52 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.52 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16577412 | 1.00 | TSHR (0.52) | TSHRLMNAGRM2GRM3GRM4 | |
| SCHEMBL9893214 | 1.00 | TSHR (0.52) | TSHRLMNAGRM2GRM3GRM4 | |
| SCHEMBL4612651 | 0.86 | TSHR (0.44) | TSHRLMNAGRM2GRM3GRM4 | |
| SCHEMBL6371192 | 0.86 | TSHR (0.44) | TSHRLMNAGRM2GRM3GRM4 | |
| SCHEMBL18199 | 0.85 | TSHR (0.45) | TSHRLMNAGRM2GRM3GRM4 | |
| SCHEMBL34475817 | 0.85 | GRM2 (0.42) | TSHRLMNAGRM2GRM3GRM4 | |
| Lithium SCHEMBL8042771 | 0.83 | TSHR (0.43) | TSHRLMNAGRM2GRM3GRM4 | |
| Hydrochloric Acid SCHEMBL3997454 | 0.83 | TSHR (0.43) | TSHRLMNAGRM2GRM3GRM4 | |
| SCHEMBL27685559 | 0.83 | GRM2 (0.34) | TSHRLMNAGRM2GRM3GRM4 | |
| SCHEMBL20221354 | 0.81 | GRM2 (0.33) | TSHRLMNAGRM2GRM3GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4188379-B1 | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA | MERCK SHARP & DOHME LLC (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-12-11 | — | — | US | disclosed |
| US-12466805-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| US-20250223276-A1 | Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of Treatment | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-07-10 | — | — | US | disclosed |
| EP-4572762-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| US-12338248-B2 | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-06-24 | — | — | US | disclosed |
| WO-2025125666-A1 | SUBSTITUTED IMIDAZOLES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2025-06-19 | — | — | WO | disclosed |
| EP-4568959-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| WO-2013106520-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013106520-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2582670-A1 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20120149733-A1 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-14 | — | — | US | disclosed |
| US-20120149733-A1 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-14 | — | — | US | disclosed |
| US-20120149733-A1 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-14 | — | — | US | disclosed |
| WO-2011159852-A1 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159852-A1 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466805-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | TSHR 4512/4885LMNA 3830/4885GRM2 4605/4885 |
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | TSHR 1260/4885LMNA 974/4885GRM2 2773/4885 |
| US-12338248-B2 | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors | CDK6, CDK2, CDK8 | TSHR 4434/4885LMNA 2401/4885GRM2 2856/4885 |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | TSHR 4427/4885LMNA 4392/4885GRM2 4675/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | TSHR 2456/4885LMNA 1117/4885GRM2 1120/4885 |
| US-20250223276-A1 | Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of Treatment | HCRTR2, HCRTR1, CNR2 | TSHR 1953/4885LMNA 1405/4885GRM2 96/4885 |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | TSHR 1206/4885LMNA 471/4885GRM2 2295/4885 |
| US-20120149733-A1 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | CCR2, CCR5, CCL11 | TSHR 1068/4885LMNA 4346/4885GRM2 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.